Ftse Mib
34.683,22
0,55%
DAX
18.608,16
0,68%
S&P 500
5.268,88
-0,16%
NASDAQ
16.797,44
0,37%
Bitcoin
69.470,56
2,54%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Kaleido Biosciences Inc (KLDO) Kaleido Biosciences Inc (KLDO) Notizie

KLDO

Kaleido Biosciences (KLDO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KLDO
DataOraFonteTitoloSimboloCompagnia
06/05/202214:16Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:KLDOKaleido Biosciences Inc
02/05/202212:20Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:KLDOKaleido Biosciences Inc
27/04/202211:03TipRanksAnalysts Offer Insights on Healthcare Companies: and Kaleido Biosciences (KLDO)NASDAQ:KLDOKaleido Biosciences Inc
25/04/202222:43Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:KLDOKaleido Biosciences Inc
18/04/202215:25Edgar (US Regulatory)Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)NASDAQ:KLDOKaleido Biosciences Inc
08/04/202215:26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KLDOKaleido Biosciences Inc
04/04/202213:45TipRanksKaleido Biosciences (KLDO) was Downgraded to a Hold Rating at Chardan CapitalNASDAQ:KLDOKaleido Biosciences Inc
16/03/202213:30GlobeNewswire Inc.Radius Health Announces Leadership AppointmentsNASDAQ:KLDOKaleido Biosciences Inc
02/03/202222:16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KLDOKaleido Biosciences Inc
28/02/202215:00PR Newswire (US)Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory AffairsNASDAQ:KLDOKaleido Biosciences Inc
15/02/202216:05PR Newswire (US)INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANTNASDAQ:KLDOKaleido Biosciences Inc
09/02/202215:25Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:KLDOKaleido Biosciences Inc
21/01/202217:04GlobeNewswire Inc.Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn’s and Colitis CongressNASDAQ:KLDOKaleido Biosciences Inc
16/12/202123:17Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:KLDOKaleido Biosciences Inc
06/12/202113:30GlobeNewswire Inc.Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic ConditionsNASDAQ:KLDOKaleido Biosciences Inc
15/11/202113:30GlobeNewswire Inc.Kaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ConferenceNASDAQ:KLDOKaleido Biosciences Inc
10/11/202113:30GlobeNewswire Inc.Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical OfficerNASDAQ:KLDOKaleido Biosciences Inc
01/11/202112:30GlobeNewswire Inc.Kaleido Biosciences Reports Third Quarter 2021 Financial ResultsNASDAQ:KLDOKaleido Biosciences Inc
13/10/202116:11PR Newswire (US)Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate ChangeNASDAQ:KLDOKaleido Biosciences Inc
12/10/202113:30GlobeNewswire Inc.Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics SummitNASDAQ:KLDOKaleido Biosciences Inc
05/10/202113:00GlobeNewswire Inc.Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative ColitisNASDAQ:KLDOKaleido Biosciences Inc
29/09/202113:30GlobeNewswire Inc.Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021NASDAQ:KLDOKaleido Biosciences Inc
02/09/202123:26Edgar (US Regulatory)Post-effective Amendment Filed Solely to Add Exhibits to a Registration Statement (pos Ex)NASDAQ:KLDOKaleido Biosciences Inc
02/09/202113:30GlobeNewswire Inc.Kaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare ConferenceNASDAQ:KLDOKaleido Biosciences Inc
11/08/202113:37Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KLDOKaleido Biosciences Inc
11/08/202113:30GlobeNewswire Inc.Kaleido Biosciences Reports Second Quarter 2021 Financial ResultsNASDAQ:KLDOKaleido Biosciences Inc
10/08/202113:30GlobeNewswire Inc.Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical TrialNASDAQ:KLDOKaleido Biosciences Inc
09/08/202122:15GlobeNewswire Inc.Kaleido Biosciences Announces New Chairperson Appointment to its Board of DirectorsNASDAQ:KLDOKaleido Biosciences Inc
06/08/202113:30GlobeNewswire Inc.Kaleido Biosciences to Participate in the 41st Annual Canaccord Genuity Growth ConferenceNASDAQ:KLDOKaleido Biosciences Inc
10/06/202113:30GlobeNewswire Inc.Kaleido Biosciences to Participate in the JMP Securities Life Sciences ConferenceNASDAQ:KLDOKaleido Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KLDO

La tua Cronologia

UPBT
BOXXBTC
Blockparty
DOWI
DJTMDI
DJ Media Titans 30
NASDAQ
FLGC
Flora Growth
TSX
DRFC
Desjardins RI Canada Mul...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network